FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Open Access
- 1 April 2011
- journal article
- retracted article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (4) , 1361-1372
Abstract
The limited success of cancer immunotherapy is often attributed to the loss of antigen-specific T cell function in situ. However, the mechanism for this loss of function is unknown. In this study, we describe a population of tumor-associated DCs (TADCs) in both human and mouse prostate cancer that tolerizes and induces suppressive activity in tumor-specific T cells. In tumors from human prostate cancer patients and transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, TADCs expressed elevated levels of FOXO3 and Foxo3, respectively, which correlated with expression of suppressive genes that negatively regulate T cell function. Silencing FOXO3 and Foxo3 with siRNAs abrogated the ability of human and mouse TADCs, respectively, to tolerize and induce suppressive activity by T cells. Silencing Foxo3 in mouse TADCs was also associated with diminished expression of tolerogenic mediators, such as indoleamine-2,3-dioxygenase, arginase, and TGF-β, and upregulated expression of costimulatory molecules and proinflammatory cytokines. Importantly, transfer of tumor-specific CD4+ Th cells into TRAMP mice abrogated TADC tolerogenicity, which was associated with reduced Foxo3 expression. These findings demonstrate that FOXO3 may play a critical role in mediating TADC-induced immune suppression. Moreover, our results identify what we believe to be a novel target for preventing CTL tolerance and enhancing immune responses to cancer by modulating the immunosuppressive activity of TADCs found in the tumor microenvironment.Keywords
This publication has 55 references indexed in Scilit:
- Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and CysteineCancer Research, 2010
- Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic CellsCancer Research, 2009
- Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cellsNature Immunology, 2009
- Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via l-Arginine MetabolismCancer Research, 2009
- Melanoma Progression Despite Infiltration by In Vivo-primed TRP-2–specific T CellsJournal of Immunotherapy, 2009
- The Janus face of dendritic cells in cancerOncogene, 2008
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseJournal of Clinical Investigation, 2007
- Adoptive T cell therapy for cancer in the clinicJournal of Clinical Investigation, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCRNucleic Acids Research, 2002